Arthur Ryan Sells 200 Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Arthur Ryan sold 200 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Regeneron Pharmaceuticals Trading Down 2.0%

REGN opened at $662.88 on Thursday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $821.11. The company has a fifty day moving average of $647.01 and a 200-day moving average of $723.51. The stock has a market cap of $70.08 billion, a PE ratio of 16.15, a price-to-earnings-growth ratio of 1.49 and a beta of 0.24. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. During the same period last year, the business posted $8.22 EPS. The business’s revenue was up 19.0% compared to the same quarter last year. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.4 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Benchmark upgraded Regeneron Pharmaceuticals to buy from hold, indicating improved confidence in the stock’s outlook and valuation. Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Increased to Buy at Benchmark
• Positive Sentiment: Several analysts still see upside in REGN despite trimming price targets, including Truist and other firms that maintained bullish ratings, suggesting Wall Street remains constructive on the company’s fundamentals. Regeneron price target changes
• Positive Sentiment: Zacks highlighted Regeneron as a strong value stock with a solid earnings surprise history, which may help support sentiment ahead of its next results. Here's Why Regeneron (REGN) is a Strong Value Stock
• Neutral Sentiment: Royal Bank of Canada cut its price target to $696 and kept a sector perform rating, signaling a more cautious but not outright bearish view. Regeneron Pharmaceuticals had its price target lowered by Royal Bank Of Canada
• Neutral Sentiment: Broader biotech optimism, including comments that the sector could become “the hottest group in the market,” may provide some support, though this was not specific to Regeneron. Jim Cramer Calls Biotech “The Hottest Group in the Market”
• Negative Sentiment: Director Arthur F. Ryan sold 200 shares in a pre-arranged Rule 10b5-1 transaction, which can weigh on sentiment even though the sale was small. SEC filing for director sale
• Negative Sentiment: Morgan Stanley also lowered its price target on Regeneron, adding to the sense that analysts are tempering near-term expectations for the stock. Morgan Stanley price target cut

Analysts Set New Price Targets

Several brokerages have recently commented on REGN. Benchmark raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research report on Tuesday. Wells Fargo & Company cut their target price on shares of Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a research note on Monday, May 18th. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating for the company in a report on Tuesday. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Finally, Leerink Partners reiterated a “market perform” rating and set a $641.00 price objective (down from $792.00) on shares of Regeneron Pharmaceuticals in a report on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $787.71.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Atwood & Palmer Inc. increased its stake in Regeneron Pharmaceuticals by 1.5% during the 2nd quarter. Atwood & Palmer Inc. now owns 42,332 shares of the biopharmaceutical company’s stock valued at $26,396,000 after purchasing an additional 630 shares in the last quarter. Palouse Capital Management Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 6.2% in the second quarter. Palouse Capital Management Inc. now owns 2,479 shares of the biopharmaceutical company’s stock valued at $1,546,000 after buying an additional 145 shares in the last quarter. Czech National Bank grew its holdings in shares of Regeneron Pharmaceuticals by 3.6% during the second quarter. Czech National Bank now owns 28,442 shares of the biopharmaceutical company’s stock valued at $17,735,000 after buying an additional 989 shares during the last quarter. PensionDanmark Pensionsforsikringsaktieselskab grew its holdings in shares of Regeneron Pharmaceuticals by 17.6% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 24,190 shares of the biopharmaceutical company’s stock valued at $15,083,000 after buying an additional 3,619 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its position in shares of Regeneron Pharmaceuticals by 17.9% during the second quarter. Assenagon Asset Management S.A. now owns 244,927 shares of the biopharmaceutical company’s stock worth $152,722,000 after acquiring an additional 37,139 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.